-
Blood Cancer Research Partnership’s (BCRP) mission is to provide innovative clinical trials to patients closer to their home. Far too often, patients diagnosed with cancer do not have access to ground-breaking trials due to lack of proximity to large medical centers.
BCRP’s main objective is to bring the novel trials to the patients across the country. We believe the collaboration between community oncologists and Dana-Farber Cancer Institute physicians will accelerate the advancement of and expansion of access to well-designed and innovative clinical trials for blood cancer patients being treated at community sites.
Members
-
Dana-Farber Cancer Institute, a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It provides adult cancer care with Brigham and Women’s Hospital as Dana-Farber/Brigham and Women’s Cancer Center and it provides pediatric care with Boston Children’s Hospital as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
-
Leukemia and Lymphoma Society, the world's largest voluntary health agency dedicated to blood cancer. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
-
LLS Therapy Acceleration Program (TAP), a strategic initiative to speed the development of blood cancer treatments and supportive diagnostics. The Clinical Trials Division of LLS TAP helps patients gain easier access to clinical trial studies in the community and familiar settings.
Contact BCRP
For more information, contact:
Alexandra Savell
Phone: 617-632-3539
Email:
BCRP@dfci.harvard.edu